List view / Grid view
1 February 2018 | By PerkinElmer
This webinar discussed a screening assay that recapitulates the activation of ER stress sensor IRE1 and an assay to quantify cell migration phenotypes, as applied to cardiovascular target validation and drug discovery.
Reasons for phenotypic vs. target based drug discovery strategies, challenges of and maximising return of phenotypic assays.
Water immersion lenses provide: brighter images from HCS samples; faster and gentler imaging; higher quality images from both 2D and 3D samples.
Large, human cardiac-muscle patches created in the lab have been tested, for the first time, on large animals the patches significantly improved recovery from heart attack injury...
In this application note, PerkinElmer demonstrates the ease and utility of the AlphaScreen® cAMP assay for detecting both agonist and antagonist-induced cAMP responses within cells.
In this application note, PerkinElmer demonstrates how LANCE® Ultra, a homogeneous assay format, can be used to quickly and accurately assess modulation of pSTAT3.
In this scientific poster, PerkinElmer demonstrates the ease and utility of using AlphaLISA® and LANCE® TR-FRET homogenous assay forms for studying PPIs.
Hits identified in high-throughput screens are evaluated within the hit-to-lead phase of drug discovery, where they undergo an iterative optimisation process employing a variety of techniques to identify promising lead compounds to move forward to the lead optimisation phase.
DiscoverX recently introduced the single donor-derived KILR CD16 Effector Cells to ensure assay reproducibility for screening, characterisation, and QC lot release of antibody drugs.
One of the biggest challenges facing drug discovery across all therapeutic modalities (small molecule, biologics, and cellular) remains the balance between physiological relevance and throughput.
Charles River Laboratories International, Inc. announced that its team of neuroscience drug discovery experts is presenting 27 scientific posters, both independently and collaboratively with clients, at Neuroscience 2017, the 47th annual meeting of the Society for Neuroscience (SfN).
6 October 2017 | By DiscoverX Corporation
In this webinar, we discussed how two qualification studies on KILR CD16 Effector Cells demonstrated accuracy and precision in different assays formats.
In this application note, IntelliCyt Corporation demonstrate a fast, efficient, radioactivity-free CMC assay with low sample input requirements, enabling miniaturisation to 384-well plates, using the iQue® Screener...
In this application note IntelliCyt Corporation report on the development and validation of their family of MultiCyt QBeads for the detection of cytokines in a high-throughput screening application on the iQue Screener...
Physiologically relevant models to evaluate the effects of drug candidates early in the drug discovery and development process are becoming increasingly important to develop. Various 3D cell/tissue models have emerged offering relevant environment for ex vivo assays, but significant progress is required to streamline and automate the end-to-end workflow. Several…
